Literature DB >> 20435569

Impact of organism species on microbial eradication and development of resistance in severe gram-negative pneumonia.

S Kiem1, J J Schentag.   

Abstract

This study evaluated the species differences in microbiological outcomes of Gram-negative bacteria (GNB) causing severe pneumonia from the viewpoint of area under the concentration-time curve/MIC ratio (AUC/MIC). In total, 111 strains of GNb from 74 patients were analyzed. Overall, microbiological eradication was achieved in 88% of the cases with initial AUC/MIC>119. However, relapse often occurred when resistance developed or AUC/miC was <176. Pseudomonas aeruginosa and Enterobacter spp. were commonly involved in failed microbiological eradication and development of resistance. The AUC/MIC required for initial eradication of P. aeruginosa was much higher (478) and antibiotic resistance in P. aeruginosa and Enterobacter spp. occurred less frequently with combination therapy (10.0% vs. 67.7%). These data argue that target magnitudes of AUC/MIC to eradicate GNB differ by species. Since antibiotic resistance developed in some species of GNB despite high AUC/MIC, strategies to minimize development of resistance, including combination therapy, must be considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435569     DOI: 10.1179/joc.2010.22.2.103

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii.

Authors:  M H Rigatto; V B Ribeiro; D Konzen; A P Zavascki
Journal:  Infection       Date:  2012-11-04       Impact factor: 3.553

2.  Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia.

Authors:  Owen R Albin; Oryan Henig; Twisha S Patel; Thomas S Valley; Jason M Pogue; Lindsay A Petty; John P Mills; Adamo Brancaccio; Emily T Martin; Keith S Kaye
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.